Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 42Carcinoma, Non-Small-Cell Lung 13Carcinoma, Renal Cell 10Colorectal Neoplasms 9Neoplasm Metastasis 8Ovarian Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Neoplasms 6Breast Neoplasms 6Stomach Neoplasms 5Pancreatic Neoplasms 5Lung Neoplasms 5Head and Neck Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Ovarian Epithelial 4Uveal Melanoma 3Esophageal Neoplasms 3Brain Neoplasms 3Triple Negative Breast Neoplasms 2Skin Neoplasms 2Sezary Syndrome 2Sarcoma 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Mycosis Fungoides 2Melanoma, Cutaneous Malignant 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2

Interventions

pembrolizumab 1Temozolomide 1Paclitaxel 1Dacarbazine 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Melanoma × Paclitaxel × Dermatologic × Clear all
NCT07310784 2026-05-12

A Phase II Trial of LM103 in Advanced Melanoma

Suzhou BlueHorse Therapeutics Co., Ltd.

Phase 2 Recruiting
92 enrolled
Dermatologic

Advanced Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡